in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Ranbaxy Buys 13 Drugs from BMS
7:04 AM MDT | August 6, 2007 | Chemical Week Editorial Staff
Ranbaxy Laboratories Inc. (RLI; Princeton, NJ), a wholly owned subsidiary of Ranbaxy Laboratories (Gurgaon, India), says it has acquired the U.S. rights to 13 dermatology products from Bristol-Myers Squibb (BMS). The U.S. dermatology market is valued at about $10 billion/year. The acquired brands have been in the market for more than a decade. They will be sold in the U.S. market under the RLI label. The deal “enables Ranbaxy to establish an immediate presence in the high-value segments of dermatitis, psoriasis, antifungals, and scabies, in addition to...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee